Entropy Technologies LP raised its stake in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 111.1% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 16,519 shares of the medical research company's stock after purchasing an additional 8,693 shares during the quarter. Thermo Fisher Scientific accounts for 1.1% of Entropy Technologies LP's portfolio, making the stock its 4th biggest position. Entropy Technologies LP's holdings in Thermo Fisher Scientific were worth $10,218,000 as of its most recent filing with the SEC.
A number of other hedge funds and other institutional investors have also recently modified their holdings of TMO. Signature Resources Capital Management LLC increased its stake in Thermo Fisher Scientific by 318.2% during the 2nd quarter. Signature Resources Capital Management LLC now owns 46 shares of the medical research company's stock worth $25,000 after buying an additional 35 shares in the last quarter. New Millennium Group LLC acquired a new position in Thermo Fisher Scientific in the 2nd quarter valued at $29,000. Stephens Consulting LLC increased its holdings in Thermo Fisher Scientific by 116.0% in the 2nd quarter. Stephens Consulting LLC now owns 54 shares of the medical research company's stock valued at $30,000 after purchasing an additional 29 shares in the last quarter. Headlands Technologies LLC acquired a new stake in Thermo Fisher Scientific during the first quarter worth about $32,000. Finally, Bank & Trust Co acquired a new position in shares of Thermo Fisher Scientific during the second quarter valued at approximately $33,000. 89.23% of the stock is owned by institutional investors.
Thermo Fisher Scientific Price Performance
TMO traded down $6.29 on Tuesday, hitting $540.63. 1,723,815 shares of the stock were exchanged, compared to its average volume of 1,462,758. The firm has a market capitalization of $206.79 billion, a price-to-earnings ratio of 34.29, a PEG ratio of 3.65 and a beta of 0.79. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.63 and a quick ratio of 1.26. Thermo Fisher Scientific Inc. has a 12 month low of $439.11 and a 12 month high of $627.88. The business has a 50-day moving average of $592.59 and a two-hundred day moving average of $583.56.
Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its quarterly earnings results on Wednesday, October 23rd. The medical research company reported $5.28 earnings per share for the quarter, topping analysts' consensus estimates of $5.25 by $0.03. The company had revenue of $10.60 billion for the quarter, compared to the consensus estimate of $10.63 billion. Thermo Fisher Scientific had a net margin of 14.48% and a return on equity of 17.49%. The firm's quarterly revenue was up .2% on a year-over-year basis. During the same period in the previous year, the firm earned $5.69 EPS. Sell-side analysts forecast that Thermo Fisher Scientific Inc. will post 21.69 EPS for the current fiscal year.
Thermo Fisher Scientific Dividend Announcement
The business also recently announced a quarterly dividend, which will be paid on Wednesday, January 15th. Stockholders of record on Friday, December 13th will be given a dividend of $0.39 per share. This represents a $1.56 annualized dividend and a dividend yield of 0.29%. The ex-dividend date is Friday, December 13th. Thermo Fisher Scientific's dividend payout ratio is currently 9.78%.
Wall Street Analysts Forecast Growth
A number of equities analysts have weighed in on the stock. Stephens assumed coverage on shares of Thermo Fisher Scientific in a research note on Tuesday, October 1st. They issued an "overweight" rating and a $680.00 target price for the company. Stifel Nicolaus lowered their price objective on shares of Thermo Fisher Scientific from $680.00 to $665.00 and set a "buy" rating for the company in a research note on Thursday, October 24th. Redburn Atlantic initiated coverage on shares of Thermo Fisher Scientific in a report on Monday, October 14th. They set a "buy" rating and a $680.00 price objective on the stock. Morgan Stanley lifted their price target on shares of Thermo Fisher Scientific from $655.00 to $680.00 and gave the company an "overweight" rating in a report on Friday, September 20th. Finally, Bernstein Bank boosted their price target on Thermo Fisher Scientific from $565.00 to $625.00 and gave the stock a "market perform" rating in a report on Tuesday, October 22nd. Four research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $649.33.
View Our Latest Report on Thermo Fisher Scientific
Insider Activity at Thermo Fisher Scientific
In other news, SVP Michael A. Boxer sold 2,000 shares of the stock in a transaction dated Friday, October 25th. The stock was sold at an average price of $560.16, for a total value of $1,120,320.00. Following the transaction, the senior vice president now directly owns 12,736 shares of the company's stock, valued at approximately $7,134,197.76. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, CEO Marc N. Casper sold 9,000 shares of the stock in a transaction on Friday, November 8th. The stock was sold at an average price of $552.86, for a total value of $4,975,740.00. Following the transaction, the chief executive officer now directly owns 14,608 shares of the company's stock, valued at approximately $8,076,178.88. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, SVP Michael A. Boxer sold 2,000 shares of the firm's stock in a transaction dated Friday, October 25th. The shares were sold at an average price of $560.16, for a total value of $1,120,320.00. Following the sale, the senior vice president now owns 12,736 shares of the company's stock, valued at $7,134,197.76. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 37,150 shares of company stock worth $20,651,865 in the last quarter. 0.34% of the stock is owned by company insiders.
About Thermo Fisher Scientific
(
Free Report)
Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.
Featured Articles
Before you consider Thermo Fisher Scientific, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Thermo Fisher Scientific wasn't on the list.
While Thermo Fisher Scientific currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.
Get This Free Report
